Redmile Group, LLC Buys ADC Therapeutics SA, Gilead Sciences Inc, Oak Street Health Inc, Sells Principia Biopharma Inc, Momenta Pharmaceuticals Inc, BioNTech SE

• New Purchases: ADCT, GILD, OSH, KYMR, RCEL, CTSO, GDRX, OM, RIGL,
• Added Positions: AKRO, BIIB, SNY, ZNTL, BCEL, IGMS, TCRR, BSX, SLQT, ZYME, ONEM, PROF, TCDA, REPL, KRYS, STOK, NLTX, ATRA, CBAY,
• Reduced Positions: BNTX, PPD, FOLD, ODT, DVAX, CI, AMED, AXNX, ALLK, DCPH, IMVT, ARGX, IMMU, ICUI, NVTA, IMGN, CTLT, EIDX, DXCM, QURE, NVRO, WVE, EPZM, GNMK, CABA,
• Sold Out: PRNB, MNTA, HRC, CYRX, MRK, NVS, GMAB, UNH, TWST, GH, RPRX, ELGXQ,

For the details of Redmile Group, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/redmile+group%2C+llc/current-portfolio/portfolio

1. Fate Therapeutics Inc (FATE) - 12,629,737 shares, 9.86% of the total portfolio.
2. Amicus Therapeutics Inc (FOLD) - 23,075,807 shares, 6.37% of the total portfolio. Shares reduced by 7.49%
3. Immunomedics Inc (IMMU) - 3,234,934 shares, 5.37% of the total portfolio. Shares reduced by 7.31%
4. argenx SE (ARGX) - 988,468 shares, 5.07% of the total portfolio. Shares reduced by 4.48%
5. IGM Biosciences Inc (IGMS) - 3,425,455 shares, 4.94% of the total portfolio. Shares added by 8.95%

Redmile Group, LLC initiated holding in ADC Therapeutics SA. The purchase prices were between $32.87 and $51.05, with an estimated average price of $43.3. The stock is now traded at around $35.85. The impact to a portfolio due to this purchase was 4.09%. The holding were 6,353,094 shares as of .

Redmile Group, LLC initiated holding in Gilead Sciences Inc. The purchase prices were between $62.1 and $78.08, with an estimated average price of $69.4. The stock is now traded at around $60.11. The impact to a portfolio due to this purchase was 3.54%. The holding were 2,869,962 shares as of .

Redmile Group, LLC initiated holding in Oak Street Health Inc. The purchase prices were between $39 and $53.44, with an estimated average price of $44.79. The stock is now traded at around $46.80. The impact to a portfolio due to this purchase was 2.77%. The holding were 2,652,411 shares as of .

Redmile Group, LLC initiated holding in Kymera Therapeutics Inc. The purchase prices were between $26.1 and $33.28, with an estimated average price of $30.49. The stock is now traded at around $49.86. The impact to a portfolio due to this purchase was 1.72%. The holding were 2,732,660 shares as of .

Redmile Group, LLC initiated holding in Avita Therapeutics Inc. The purchase prices were between $20.83 and $30, with an estimated average price of $25.04. The stock is now traded at around $22.70. The impact to a portfolio due to this purchase was 0.87%. The holding were 1,779,586 shares as of .

Redmile Group, LLC initiated holding in CytoSorbents Corp. The purchase prices were between $7.37 and $11.55, with an estimated average price of $9.01. The stock is now traded at around $8.98. The impact to a portfolio due to this purchase was 0.33%. The holding were 2,101,131 shares as of .

Redmile Group, LLC added to a holding in Akero Therapeutics Inc by 495.78%. The purchase prices were between $30.79 and $39.92, with an estimated average price of $34.88. The stock is now traded at around $28.93. The impact to a portfolio due to this purchase was 1.17%. The holding were 2,336,357 shares as of .

Redmile Group, LLC added to a holding in Biogen Inc by 101.75%. The purchase prices were between $264.77 and $305.71, with an estimated average price of $278.66. The stock is now traded at around $244.15. The impact to a portfolio due to this purchase was 0.91%. The holding were 327,447 shares as of .

Redmile Group, LLC added to a holding in Sanofi SA by 42.23%. The purchase prices were between $49.47 and $53.77, with an estimated average price of $51.45. The stock is now traded at around $50.52. The impact to a portfolio due to this purchase was 0.51%. The holding were 1,743,048 shares as of .

Redmile Group, LLC added to a holding in Zentalis Pharmaceuticals Inc by 46.42%. The purchase prices were between $27.03 and $47.97, with an estimated average price of $35.09. The stock is now traded at around $46.00. The impact to a portfolio due to this purchase was 0.49%. The holding were 2,432,408 shares as of .

Redmile Group, LLC added to a holding in Atreca Inc by 156.85%. The purchase prices were between $12.67 and $23.19, with an estimated average price of $15. The stock is now traded at around $14.77. The impact to a portfolio due to this purchase was 0.43%. The holding were 2,548,168 shares as of .

Redmile Group, LLC added to a holding in TCR2 Therapeutics Inc by 58.24%. The purchase prices were between $13.1 and $20.69, with an estimated average price of $17.53. The stock is now traded at around $27.16. The impact to a portfolio due to this purchase was 0.41%. The holding were 2,793,288 shares as of .

Redmile Group, LLC sold out a holding in Principia Biopharma Inc. The sale prices were between $56 and $101.07, with an estimated average price of $88.57.

Redmile Group, LLC sold out a holding in Momenta Pharmaceuticals Inc. The sale prices were between $27.91 and $52.49, with an estimated average price of $41.42.

Redmile Group, LLC sold out a holding in Hill-Rom Holdings Inc. The sale prices were between $81.17 and $117.57, with an estimated average price of $97.98.

Redmile Group, LLC sold out a holding in CryoPort Inc. The sale prices were between $31.04 and $57.99, with an estimated average price of $40.58.

Redmile Group, LLC sold out a holding in Merck & Co Inc. The sale prices were between $76.69 and $86.93, with an estimated average price of $82.09.

Redmile Group, LLC sold out a holding in Novartis AG. The sale prices were between $82.14 and $91, with an estimated average price of $86.65.